Monte Rosa Therapeutics (GLUE) traded higher in premarket after the company announced plans to begin multiple Phase 2 trials ...
Shares of Monte Rosa Therapeutics rose after the company said it will host a live conference call and webcast on Thursday at 8 a.m. Eastern to review clinical results from a recent study. The stock ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Monte Rosa Therapeutics, Inc. GLUE reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results